Related Experiment Videos
Reduction of dialyzer fibrin deposition with sulphinpyrazone
Abstract:
To determine whether sulphinpyrazone reduces thrombus formation within artificial kidneys, dialyzer 125I-fibrinogen and platelet and fibrinogen levels during dialysis were compared during a non-treatment control period and while patients were receiving sulphinpyrazone. Mean fibrin deposition within the dialyzers, measured as gram X 10(-3) of clottable fibrinogen, was significantly less during sulphinpyrazone treatment (2.5) than during the control period (5.3). Arterial blood platelet counts and plasma fibrinogen levels during dialysis were higher on treatment despite similar predialysis values during control and treatment periods. The results indicate that sulphinpyrazone reduces fibrin formation within artificial kidneys and, since the reduction in deposition of fibrin alone is insufficient to explain the higher plasma fibrinogen levels during treatment with sulphinpyrazone, suggests that this therapy reduces fibrinogen consumption within the patient during hemodialysis.
Insights
Sulphinpyrazone significantly reduces fibrin formation in artificial kidneys during dialysis. This therapy also appears to decrease fibrinogen consumption in patients undergoing hemodialysis.
Area of Science:
- Nephrology
- Hematology
- Pharmacology
Background:
- Thrombus formation in artificial kidneys is a complication during hemodialysis.
- Understanding agents that mitigate this process is crucial for patient safety and treatment efficacy.
Purpose of the Study:
- To evaluate the efficacy of sulphinpyrazone in reducing thrombus formation within artificial kidneys.
- To investigate the impact of sulphinpyrazone on platelet and fibrinogen levels during hemodialysis.
Main Methods:
- A comparative study design was employed, measuring dialyzer fibrin deposition using 125I-fibrinogen.
- Platelet and fibrinogen levels were monitored during dialysis in a control period versus a period of sulphinpyrazone treatment.
Main Results:
- Mean fibrin deposition in dialyzers was significantly lower during sulphinpyrazone treatment (2.5 g x 10(-3)) compared to the control period (5.3 g x 10(-3)).
- Arterial blood platelet counts and plasma fibrinogen levels were higher during sulphinpyrazone treatment, despite similar predialysis values.
Conclusions:
- Sulphinpyrazone effectively reduces fibrin formation within artificial kidneys during hemodialysis.
- The observed increase in plasma fibrinogen levels suggests that sulphinpyrazone may also reduce fibrinogen consumption during hemodialysis.